Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background Atopic dermatitis (AD) is a highly heterogeneous disease, both clinically and biologically, whereas patients are still being treated according to a "one-size-fits-all" approach. Stratification of patients into biomarker-based endotypes is important for future development of personalized therapies. Objective Our aim was to confirm previously defined serum biomarker-based patient clusters in a new cohort of patients with AD. Methods A panel of 143 biomarkers was measured by using Luminex technology in serum samples from 146 patients with severe AD (median Eczema Area and Severity Index = 28.3; interquartile range = 25.2-35.3). Principal components analysis followed by unsupervised k-means cluster analysis of the biomarker data was used to identify patient clusters. A prediction model was built on the basis of a previous cohort to predict the 1 of the 4 previously identified clusters to which the patients of our new cohort would belong. Results Cluster analysis identified 4 serum biomarker–based clusters, 3 of which (clusters B, C, and D) were comparable to the previously identified clusters. Cluster A (33.6%) could be distinguished from the other clusters as being a "skin-homing chemokines/IL-1R1–dominant" cluster, whereas cluster B (18.5%) was a "T H 1/T H 2/T H 17-dominant" cluster, cluster C (18.5%) was a "T H 2/T H 22/PARC-dominant" cluster, and cluster D (29.5%) was a "T H 2/eosinophil-inferior" cluster. Additionally, by using a prediction model based on our previous cohort we accurately assigned the new cohort to the 4 previously identified clusters by including only 10 selected serum biomarkers. Conclusion We confirmed that AD is heterogeneous at the immunopathologic level and identified 4 distinct biomarker-based clusters, 3 of which were comparable with previously identified clusters. Cluster membership could be predicted with a model including 10 serum biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic features of atopic dermatitis
Hanifin, J. M., & Rajka, G. (1980) · Acta Dermato-Venereologica · doi:10.2340/00015555924447 · Cited by 5,086
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Noda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657
Schmitt, J., Spuls, P. I., Thomas, K. S., Simpson, E., Furue, M., Deckert, S., Dohil, M., Apfelbacher, C., Singh, J. A., Chalmers, J., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.07.043 · Cited by 319
Zhou, L., Leonard, A., Pavel, A. B., Malik, K., Raja, A., Glickman, J., Estrada, Y. D., Peng, X., del Duca, E., Sanz-Cabanillas, J., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.01.015 · Cited by 146
Cited by
Guttman-Yassky, E., Renert-Yuval, Y., & Brunner, P. M. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02519-4 · Cited by 321
Novel insights into atopic dermatitis
Schuler, C. F., Billi, A. C., Maverakis, E., Tsoi, L. C., & Gudjonsson, J. E. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.10.023 · Cited by 281
Fania, L., Moretta, G., Antonelli, F., Scala, E., Abeni, D., Albanesi, C., & Madonna, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052684 · Cited by 128
Recent advancements in the atopic dermatitis mechanism
Savva, M., Papadopoulos, N. G., Gregoriou, S., Katsarou, S., Papapostolou, N., Makris, M., & Xepapadaki, P. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2902084 · Cited by 53
“…17, and epithelial-related chemokines, the third T H 2, T H 22, and pulmonary and activation-regulated chemokine (PARC) dominated cluster, which was associated with significantly more severe disease, and the fourth, a T H 2 and eosinophil-inferior cluster, with the least inflammatory disease [155].”
BackgroundImmunological pathomechanisms of spongiotic dermatitis in skin lesions of atopic dermatitis
Tanei, R., & Hasegawa, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126682 · Cited by 33
Metadata
- Authors
- Bakker, D. S., Nierkens, S., Knol, E. F., Giovannone, B., Delemarre, E. M., van der Schaft, J., van Wijk, F., de Bruin-Weller, M. S., Drylewicz, J., & Thijs, J. L.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 147
- Issue
- 1
- Pages
- 189-198
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W3035343152
- Cited by
- 126
- References
- 5
- FWCI
- 9.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers. https://app.cochat.ai/papers/10.1016/j.jaci.2020.04.062
- The paper
- Bakker, D. S., Nierkens, S., Knol, E. F., Giovannone, B., Delemarre, E. M., van der Schaft, J., van Wijk, F., de Bruin-Weller, M. S., Drylewicz, J., & Thijs, J. L. (2021). Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2020.04.062
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.